Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100852 · ClinicalTrials.gov registry record · Phase 1
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02100852 is a Phase 1 study that has completed, run by TG Therapeutics. The registered enrollment target is 19 participants.
The verdict
NCT02100852, a Phase 1 study, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.
Interventions
- DRUG TGR-1202 + Obinutuzumab + Chlorambucil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-03-12 |
| Est. Completion | 2017-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02100852
The ClinicalTrials.gov registry entry for NCT02100852 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TGR-1202 + Obinutuzumab + Chlorambucil is the first listed.
NCT02100852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02100852 about?
NCT02100852 is a clinical study titled "TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)". The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.
What is the current status of trial NCT02100852?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-03-12. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02100852?
The interventions under investigation include: TGR-1202 + Obinutuzumab + Chlorambucil (DRUG).
Who is sponsoring clinical trial NCT02100852?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.